These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1581 related articles for article (PubMed ID: 17108138)

  • 1. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
    Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells.
    Numbenjapon T; Serrano LM; Chang WC; Forman SJ; Jensen MC; Cooper LJ
    Exp Hematol; 2007 Jul; 35(7):1083-90. PubMed ID: 17588477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
    Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
    Lo AS; Ma Q; Liu DL; Junghans RP
    Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
    Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
    Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.
    Cheadle EJ; Hawkins RE; Batha H; O'Neill AL; Dovedi SJ; Gilham DE
    J Immunol; 2010 Feb; 184(4):1885-96. PubMed ID: 20089697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
    Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.
    Singh H; Serrano LM; Pfeiffer T; Olivares S; McNamara G; Smith DD; Al-Kadhimi Z; Forman SJ; Gillies SD; Jensen MC; Colcher D; Raubitschek A; Cooper LJ
    Cancer Res; 2007 Mar; 67(6):2872-80. PubMed ID: 17363611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
    Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning.
    Chang L; Chang WC; McNamara G; Aguilar B; Ostberg JR; Jensen MC
    Cytotherapy; 2007; 9(8):771-84. PubMed ID: 17917884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
    Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
    Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members.
    Kroon HM; Li Q; Teitz-Tennenbaum S; Whitfield JR; Noone AM; Chang AE
    J Immunother; 2007; 30(4):406-16. PubMed ID: 17457215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.
    Wang X; Wong CW; Urak R; Mardiros A; Budde LE; Chang WC; Thomas SH; Brown CE; La Rosa C; Diamond DJ; Jensen MC; Nakamura R; Zaia JA; Forman SJ
    Clin Cancer Res; 2015 Jul; 21(13):2993-3002. PubMed ID: 25838392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
    J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
    Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
    Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition.
    Condomines M; Arnason J; Benjamin R; Gunset G; Plotkin J; Sadelain M
    PLoS One; 2015; 10(6):e0130518. PubMed ID: 26110267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
    Ma Q; Gomes EM; Lo AS; Junghans RP
    Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
    Bohlen H; Manzke O; Titzer S; Lorenzen J; Kube D; Engert A; Abken H; Wolf J; Diehl V; Tesch H
    Cancer Res; 1997 May; 57(9):1704-9. PubMed ID: 9135012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells.
    Loskog A; Giandomenico V; Rossig C; Pule M; Dotti G; Brenner MK
    Leukemia; 2006 Oct; 20(10):1819-28. PubMed ID: 16932339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.